Endocrinologic and Metabolic Drugs Advisory Committee; Cancellation, 5333 [2010-2096]
Download as PDF
<![CDATA[
Federal Register / Vol. 75, No. 21 / Tuesday, February 2, 2010 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
mstockstill on DSKH9S0YB1PROD with NOTICES
Safety and Occupational Health Study
Section (SOHSS), National Institute for
Occupational Safety and Health
(NIOSH)
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC),
announces the following meeting of the
aforementioned committee:
Times and Dates:
8 a.m.–5 p.m., February 17, 2010.
(Closed)
8 a.m.–5 p.m., February 18, 2010.
(Closed)
Place: Embassy Suites Hotel, 1900
Diagonal Road, Alexandria, Virginia
22314, Telephone (703) 684–5900, Fax
(703) 684–1403.
Status: These portions of the meeting
will be closed to the public in
accordance with provisions set forth in
Section 552b(c)(4) and (6), Title 5
U.S.C., and the Determination of the
Director, Management Analysis and
Services Office, Centers for Disease
Control and Prevention, pursuant to
Section 10(d) Public Law 92–463.
Purpose: The Safety and Occupational
Health Study Section will review,
discuss, and evaluate grant
application(s) received in response to
the Institute’s standard grants review
and funding cycles pertaining to
research issues in occupational safety
and health, and allied areas.
It is the intent of NIOSH to support
broad-based research endeavors in
keeping with the Institute’s program
goals. This will lead to improved
understanding and appreciation for the
magnitude of the aggregate health
burden associated with occupational
injuries and illnesses, as well as to
support more focused research projects,
which will lead to improvements in the
delivery of occupational safety and
health services, and the prevention of
work-related injury and illness. It is
anticipated that research funded will
promote these program goals.
Matters To Be Discussed: The meeting
will convene to address matters related
to the conduct of Study Section
business and for the study section to
consider safety and occupational healthrelated grant applications.
Agenda items are subject to change as
priorities dictate.
For More Information Contact: Price
Connor, PhD, NIOSH Health Scientist,
1600 Clifton Road, NE., Mailstop E–20,
VerDate Nov<24>2008
16:52 Feb 01, 2010
Jkt 220001
Atlanta, Georgia 30333, Telephone (404)
498–2511, Fax (404) 498–2571.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities for both CDC and
the Agency for Toxic Substances and
Disease Registry.
Dated: January 25, 2010.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2010–2117 Filed 2–1–10; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2010–N–0001]
Endocrinologic and Metabolic Drugs
Advisory Committee; Cancellation
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
SUMMARY: The meeting of the
Endocrinologic and Metabolic Drugs
Advisory Committee scheduled for
February 24, 2010, is cancelled. This
meeting was announced in the Federal
Register of January 19, 2010 (75 FR
2875). This meeting has been cancelled
due to unexpected delays in the
preparation of materials for the meeting.
The agency will reschedule this meeting
and announce a future meeting date in
the Federal Register.
FOR FURTHER INFORMATION CONTACT: Paul
Tran, Center for Drug Evaluation and
Research (HFD–21), Food and Drug
Administration, 5600 Fishers Lane (for
express delivery, 5630 Fishers Lane, rm.
1093), Rockville, MD 20857, 301–827–
7001, FAX: 301–827–6776, e-mail:
paul.tran@fda.hhs.gov, or FDA
Advisory Committee Information Line,
1–800–741–8138 (301–443–0572 in the
Washington, DC area), code
3014512536. Please call the Information
Line for up-to-date information on this
meeting.
Dated: January 26, 2010.
Jill Hartzler Warner,
Acting Associate Commissioner for Special
Medical Programs.
[FR Doc. 2010–2096 Filed 2–1–10; 8:45 am]
BILLING CODE 4160–01–S
PO 00000
Frm 00055
Fmt 4703
Sfmt 4703
5333
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2010–N–0001]
Pulmonary-Allergy Drugs Advisory
Committee; Notice of Meeting
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
This notice announces a forthcoming
meeting of a public advisory committee
of the Food and Drug Administration
(FDA). The meeting will be open to the
public.
Name of Committee: PulmonaryAllergy Drugs Advisory Committee.
General Function of the Committee:
To provide advice and
recommendations to the agency on
FDA’s regulatory issues.
Date and Time: The meeting will be
held on March 9, 2010, from 8 a.m. to
5 p.m.
Location: Hilton Washington DC/
Silver Spring, The Ballrooms, 8727
Colesville Rd, Silver Spring, MD, 301–
589–5200.
Contact Person: Kristine T. Khuc,
Center for Drug Evaluation and Research
(HFD–21), Food and Drug
Administration, 5600 Fishers Lane (for
express delivery, 5630 Fishers Lane, rm.
1093), Rockville, MD 20857, 301–827–
7001, FAX: 301–827–6776, e-mail:
Kristine.Khuc@fda.hhs.gov, or FDA
Advisory Committee Information Line,
1–800–741–8138 (301–443–0572 in the
Washington, DC area), code
3014512545. Please call the Information
Line for up-to-date information on this
meeting. A notice in the Federal
Register about last minute modifications
that impact a previously announced
advisory committee meeting cannot
always be published quickly enough to
provide timely notice. Therefore, you
should always check the agency’s Web
site and call the appropriate advisory
committee hot line/phone line to learn
about possible modifications before
coming to the meeting.
Agenda: On March 9, 2010, the
committee will discuss new drug
application (NDA) 22–535, pirfenidone,
by InterMune. The proposed indication
(purpose) of this drug is the treatment
of patients with idiopathic pulmonary
fibrosis (scarring of the lungs without a
known cause) to decrease the decline in
lung function associated with this
condition.
FDA intends to make background
material available to the public no later
than 2 business days before the meeting.
If FDA is unable to post the background
E:\FR\FM\02FEN1.SGM
02FEN1
]]>Agencies
[Federal Register Volume 75, Number 21 (Tuesday, February 2, 2010)]
[Notices]
[Page 5333]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-2096]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2010-N-0001]
Endocrinologic and Metabolic Drugs Advisory Committee;
Cancellation
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The meeting of the Endocrinologic and Metabolic Drugs Advisory
Committee scheduled for February 24, 2010, is cancelled. This meeting
was announced in the Federal Register of January 19, 2010 (75 FR 2875).
This meeting has been cancelled due to unexpected delays in the
preparation of materials for the meeting. The agency will reschedule
this meeting and announce a future meeting date in the Federal
Register.
FOR FURTHER INFORMATION CONTACT: Paul Tran, Center for Drug Evaluation
and Research (HFD-21), Food and Drug Administration, 5600 Fishers Lane
(for express delivery, 5630 Fishers Lane, rm. 1093), Rockville, MD
20857, 301-827-7001, FAX: 301-827-6776, e-mail: paul.tran@fda.hhs.gov,
or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-
0572 in the Washington, DC area), code 3014512536. Please call the
Information Line for up-to-date information on this meeting.
Dated: January 26, 2010.
Jill Hartzler Warner,
Acting Associate Commissioner for Special Medical Programs.
[FR Doc. 2010-2096 Filed 2-1-10; 8:45 am]
BILLING CODE 4160-01-S
